STUDY OF THE CELL-FREE CIRCULATING DNA (ccfDNA) INTEGRITY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Main Article Content
Abstract
Objective: Study the concentration and the integrity of ccfDNA in plasmaand then assess the relation to some characteristics of non-small cell lung cancer (NSCLC) patients. Subjects andmethods: A case-control study with 50 NSCLC patients and 50 healthy controls without cancers, accompanying systemic autoimmune diseases recruited for the study at the Outpatient Department and Oncology Department of Bac Ninh General Hospital during the period from August 2022 to October 2023. Results: The average concentration of ALU-115 in the blood of cases (81.25±48.36 ng/mL) was significantly higher than that in the control group (8.63±17.89 ng/mL), ALU-247 concentration in cases group (51.75±40.25 ng/mL) was significantly increased in than the control group (2.67±3.39 ng/mL), the ratio of ALU-247/ALU-115 in the cases group (0.65± 0.25) significantly higher than the control group (0.52±0.27). When analyzing the power of diagnostic test using the ROC curve for ALU-247 (AUC=96.692%, p<0.001, Se: 94%, Sp: 96%), ALU-115 (96.8%, p<0.001, Se: 100%, Sp: 86%), ALU-247/ALU-115 ratio (64.12%, p=0.015, Se: 86%, Sp: 46%) all have high power for the detectionof NSCLC disease. Conclusion: Concentrations of ALU-115, ALU-247 biomarkers, and ALU-247/ALU-115 ratio increased in NSCLC patients and tended to increase with the stage of the disease. These biomarkershad the potential in early diagnosisand treatment of NSCLC
Article Details
References


2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc Mayo Clin. 2008;83(5):584-594.

3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi:10.3322/caac.20107


4. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer | Nature Reviews Clinical Oncology. Accessed October 30, 2023. https://www.nature. com/articles/nrclinonc.2010.220

5. De Mattos-Arruda L, Cortes J, Santarpia L, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol. 2013;10(7): 377-389. doi: 10.1038/ nrclinonc.2013.80


6. Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU Repeats | Clinical Chemistry | Oxford Academic. Accessed October 30, 2023. https://academic.oup.com/clinchem/article/52/6/1062/5627032

7. Hussein NA, Mohamed SN, Ahmed MA. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer. Appl Biochem Biotechnol. 2019;187(3): 1028-1045. doi:10.1007/s12010-018-2858-4


8. Ren S, Ren X, Guo H, et al. Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis. Pers Med. 2021;18(2):129-139. doi:10.2217/pme-2020-0019


9. Waki K, Yokomizo K, Yoshiyama K, Takamori S, Komatsu N, Yamada A. Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer. Immunopharmacol Immunotoxicol. 2021;43(2):176-182. doi:10. 1080/08923973.2021.1872619

